Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
17.24
+0.42 (2.50%)
At close: Jul 24, 2026, 4:00 PM EDT
17.02
-0.22 (-1.25%)
After-hours: Jul 24, 2026, 7:34 PM EDT
Takeda Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 4,505,700 | 4,581,551 | 4,263,762 | 4,027,478 | 3,569,006 | |
Revenue Growth (YoY) | -1.66% | 7.45% | 5.87% | 12.85% | 11.61% |
Cost of Revenue | 1,571,600 | 1,580,217 | 1,426,678 | 1,244,072 | 1,106,846 |
Gross Profit | 2,934,100 | 3,001,334 | 2,837,084 | 2,783,406 | 2,462,160 |
Selling, General & Admin | 1,084,200 | 1,104,766 | 1,053,819 | 997,309 | 886,361 |
Depreciation & Amortization Expenses | 633,500 | 643,233 | 652,117 | 542,443 | 472,915 |
Research & Development | 675,900 | 730,227 | 729,924 | 633,325 | 526,087 |
Other Operating Expenses | 534,300 | 180,521 | 187,148 | 119,823 | 115,952 |
Total Operating Expenses | 2,927,900 | 2,658,747 | 2,623,008 | 2,292,900 | 2,001,315 |
Operating Income | 6,200 | 342,586 | 214,075 | 490,505 | 460,844 |
Interest Income | -2,200 | 42,563 | 58,566 | 54,283 | 8,333 |
Interest Expense | - | -210,065 | -219,850 | -169,698 | -166,607 |
Other Non-Operating Income (Expense) | -146,400 | - | - | - | - |
Total Non-Operating Income (Expense) | -148,600 | -167,502 | -161,284 | -115,415 | -158,274 |
Pretax Income | -142,400 | 175,084 | 52,791 | 375,090 | 302,571 |
Provision for Income Taxes | - | 66,941 | -91,406 | 58,052 | 72,405 |
Net Income | -142,400 | 108,143 | 144,197 | 317,038 | 230,166 |
Minority Interest in Earnings | - | - | - | 21 | 107 |
Net Income to Common | -142,400 | 108,143 | 144,197 | 317,017 | 230,059 |
Net Income Growth | - | -25.00% | -54.51% | 37.80% | -38.81% |
Shares Outstanding (Basic) | 3,150 | 3,158 | 3,129 | 3,104 | 3,127 |
Shares Outstanding (Diluted) | 3,150 | 3,211 | 3,161 | 3,140 | 3,154 |
Shares Change (YoY) | -1.88% | 1.58% | 0.67% | -0.46% | 0.23% |
EPS (Basic) | -48.38 | 34.18 | 46.05 | 102.14 | 73.57 |
EPS (Diluted) | -48.38 | 33.62 | 45.58 | 100.97 | 72.94 |
EPS Growth | - | -26.25% | -54.86% | 38.44% | -38.96% |
Free Cash Flow | 865,428 | 856,387 | 540,924 | 836,499 | 999,853 |
Free Cash Flow Growth | 1.06% | 58.32% | -35.34% | -16.34% | 11.13% |
Free Cash Flow Per Share | 274.73 | 266.73 | 171.14 | 266.42 | 316.98 |
Dividends Per Share | 200.000 | 196.000 | 188.000 | 180.000 | 180.000 |
Dividend Growth | 2.04% | 4.25% | 4.44% | 0% | 0% |
Gross Margin | 65.12% | 65.51% | 66.54% | 69.11% | 68.99% |
Operating Margin | 0.14% | 7.48% | 5.02% | 12.18% | 12.91% |
Profit Margin | -3.16% | 2.36% | 3.38% | 7.87% | 6.45% |
FCF Margin | 19.21% | 18.69% | 12.69% | 20.77% | 28.01% |
EBITDA | 727,327 | 1,103,982 | 942,077 | 1,154,905 | 1,043,995 |
EBITDA Margin | 16.14% | 24.10% | 22.10% | 28.68% | 29.25% |
EBIT | 6,200 | 342,586 | 214,075 | 490,505 | 460,844 |
EBIT Margin | 0.14% | 7.48% | 5.02% | 12.18% | 12.91% |
Effective Tax Rate | 0.00% | 38.23% | -173.15% | 15.48% | 23.93% |